AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 105 filers reported holding AERIE PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 0.20 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $83,000 | +102.4% | 5,100 | -7.2% | 0.00% | – |
| Q2 2022 | $41,000 | -18.0% | 5,498 | 0.0% | 0.00% | – |
| Q1 2022 | $50,000 | +28.2% | 5,498 | 0.0% | 0.00% | – |
| Q4 2021 | $39,000 | -38.1% | 5,498 | 0.0% | 0.00% | – |
| Q3 2021 | $63,000 | -98.0% | 5,498 | -97.2% | 0.00% | -100.0% |
| Q2 2021 | $3,091,000 | -10.4% | 193,067 | 0.0% | 0.00% | -40.0% |
| Q1 2021 | $3,450,000 | +4380.5% | 193,067 | +3295.5% | 0.01% | – |
| Q4 2020 | $77,000 | +14.9% | 5,686 | 0.0% | 0.00% | – |
| Q3 2020 | $67,000 | -20.2% | 5,686 | 0.0% | 0.00% | – |
| Q2 2020 | $84,000 | +21.7% | 5,686 | +11.5% | 0.00% | – |
| Q1 2020 | $69,000 | -43.9% | 5,100 | 0.0% | 0.00% | – |
| Q4 2019 | $123,000 | +25.5% | 5,100 | 0.0% | 0.00% | – |
| Q3 2019 | $98,000 | -78.4% | 5,100 | -66.7% | 0.00% | – |
| Q2 2019 | $453,000 | +87.2% | 15,300 | +200.0% | 0.00% | – |
| Q1 2019 | $242,000 | -88.9% | 5,100 | -91.6% | 0.00% | -100.0% |
| Q4 2018 | $2,190,000 | -55.9% | 60,674 | -24.8% | 0.00% | -50.0% |
| Q3 2018 | $4,965,000 | -0.7% | 80,674 | +9.0% | 0.01% | -11.1% |
| Q2 2018 | $5,001,000 | +40.8% | 74,033 | +13.0% | 0.01% | +50.0% |
| Q1 2018 | $3,553,000 | +13.0% | 65,499 | +24.5% | 0.01% | 0.0% |
| Q4 2017 | $3,144,000 | +110.3% | 52,620 | +71.1% | 0.01% | +100.0% |
| Q3 2017 | $1,495,000 | +145.1% | 30,760 | +165.2% | 0.00% | +200.0% |
| Q2 2017 | $610,000 | +7.0% | 11,600 | -75.3% | 0.00% | 0.0% |
| Q1 2016 | $570,000 | -55.3% | 46,889 | -10.4% | 0.00% | -66.7% |
| Q4 2015 | $1,275,000 | +31.3% | 52,341 | -4.4% | 0.00% | +50.0% |
| Q3 2015 | $971,000 | +32.8% | 54,762 | +32.2% | 0.00% | +100.0% |
| Q2 2015 | $731,000 | -42.8% | 41,433 | +1.7% | 0.00% | -66.7% |
| Q1 2015 | $1,277,000 | +26.7% | 40,733 | +18.0% | 0.00% | +50.0% |
| Q4 2014 | $1,008,000 | +49.6% | 34,533 | +6.0% | 0.00% | +100.0% |
| Q3 2014 | $674,000 | +110.0% | 32,582 | +151.1% | 0.00% | 0.0% |
| Q2 2014 | $321,000 | – | 12,976 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 246,563 | $2,244,000 | 1.36% |
| LEVIN CAPITAL STRATEGIES, L.P. | 1,435,876 | $13,066,000 | 1.26% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4,695,020 | $42,725,000 | 0.96% |
| DCF Advisers, LLC | 189,565 | $1,725,000 | 0.76% |
| DAFNA Capital Management LLC | 289,040 | $2,630,000 | 0.68% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,678,609 | $15,275,000 | 0.61% |
| Rhenman & Partners Asset Management AB | 589,200 | $5,362,000 | 0.53% |
| PFM Health Sciences, LP | 1,088,566 | $9,906,000 | 0.37% |
| NEXPOINT ASSET MANAGEMENT, L.P. | 309,778 | $2,819,000 | 0.36% |
| Granahan Investment Management | 1,588,944 | $14,459,000 | 0.36% |